A Study of GC203 TIL in Advanced Malignant Solid Tumors

NCT ID: NCT06375187

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-29
• Study Completion Date: 2027-05-01

Brief Summary

A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors

Conditions

Solid Tumor; Gynecologic Cancer; Breast Cancer; Gastrointestinal Cancer; Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Arm

Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL)

Group Type: EXPERIMENTAL

Engineering Tumor Infiltrating Lymphocytes

Intervention Type: BIOLOGICAL

A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.

Interventions

Engineering Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.

Intervention Type: BIOLOGICAL

Other Intervention Names

GC203 TIL

Eligibility Criteria

Inclusion Criteria

• 1. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.

2. Patients must be ≥18 and ≤75 years of age at the time of consent. 3. Patients with advanced metastatic solid tumors with clear pathological diagnosis have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery]) , including but not limited to gynecological tumors (ovarian cancer, endometrial cancer, cervical cancer), breast cancer, gastrointestinal Cancer, lung cancer.

4. Patients have feasible tissue areas for tumor resection/puncture to generate GC203 TIL, the total volume of the tissue > 400mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency therapy, oncolytic virus, etc.) or has progressed after local treatment; 5. At least one measurable target lesion before preconditioning, as defined by RECIST1.1.

6. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

7. Patients must have an estimated life expectancy of ≥3 months. 8. Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:

• Absolute Neutrophil Count (ANC)≥1.0×10^9/L;
• Absolute Lymphocyte Count(ALC)≥0.5×10^9/L;
• Platelet≥80×10^9/L；
• International Normalized Ratio（INR）≤1.5×ULN;
• Activated Partial Thromboplastin Time（APTT）≤1.5×ULN;
• Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min
• Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g;
• Alanine aminotransferase(AST/SGOT) ≤3×ULN;
• Alanine aminotransferase (ALT/SGPT) ≤3×ULN;
• Total Bilirubin(TBIL)≤1.5×ULN； 9. Women of child-bearing potential (WCBP), must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study.

10. Patients must have no contraindications for surgery or biopsy. 11. Patients have good compliance and be able to adhere to research access plans and other protocol requirements.

Exclusion Criteria

1. Participate in clinical trials of other drugs or biologic therapies within 4 weeks before enrollment;

2. Participants who have had a history of allogeneic T cell therapy; gene engineering autologous cell therapy within 1 years.

3. Patients who have received systemic antitumor therapy within 4 weeks.

4. Patients who have had another primary malignancy within the previous 5 years

5. Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment

6. Patients with a history of hypersensitivity to any component of the study drugs

7. Patients who are pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Juncell Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Huajun Jin, PhD

Role: CONTACT

clinicaltrials@juncell.com

+8621-69110327

Xiaohua Wu, Phd

Role: CONTACT

Wu.xh@fudan.edu.cn

+862165675209

Facility Contacts

Xiaohua Wu, PhD

Role: primary

Wu.xh@fudan.edu.cn

+862164175590

Other Identifiers

GC203 TIL-ST-Ⅰ

Identifier Type: -

Identifier Source: org_study_id